Showing results (231-240 of 716) with videos related to
Sort By:
Pageof 72
Leukemia Research|November 18, 2008
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation statusNitin Jain, Jorge Cortes, Alfonso Quintás-Cardama, et al.Leukemia Research|November 29, 2013
Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centersCecilia Arana Yi, Ghayathri Jeyakumar, Pedro Medina, et al.Journal of Translational Medicine|September 12, 2015
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosisCatriona Jamieson, Robert Hasserjian, Jason Gotlib, et al.Hematology Reports|November 24, 2025
Outcomes for Primary Central Nervous System Lymphoma from a Single InstitutionSruthi Dontu, Jacob Boccucci, Michael Chahin, et al.Leukemia & Lymphoma|August 6, 2016
Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical studyKiran Naqvi, Naval Daver, Naveen Pemmaraju, et al.Blood|September 27, 2008
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitorsElias Jabbour, Hagop M Kantarjian, Dan Jones, et al.Blood|June 18, 2009
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significanceDushyant Verma, Hagop M Kantarjian, Dan Jones, et al.Clinical Lymphoma, Myeloma & Leukemia|January 16, 2013
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failureElias Jabbour, Hagop Kantarjian, Hady Ghanem, et al.Cancer|March 24, 2010
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intoleranceHagop Kantarjian, Phillipp le Coutre, Jorge Cortes, et al.Leukemia & Lymphoma|August 15, 2019
Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review studyJorge Cortes, Lynn Huynh, Estella Mendelson, et al.Pageof 72